Avalide: Comprehensive Blood Pressure Control in a Single Tablet
| Product dosage: 162.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.89 | $56.76 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $113.52 $86.00 (24%) | 🛒 Add to cart |
| 90 | $1.27 | $170.28 $114.38 (33%) | 🛒 Add to cart |
| 120 | $1.19 | $227.04 $142.76 (37%) | 🛒 Add to cart |
| 180 | $1.11 | $340.56 $200.38 (41%) | 🛒 Add to cart |
| 270 | $1.06
Best per pill | $510.84 $286.38 (44%) | 🛒 Add to cart |
Synonyms | |||
Avalide combines two proven antihypertensive agents—irbesartan and hydrochlorothiazide—into a single, convenient tablet designed for patients requiring multiple medications to achieve blood pressure targets. This fixed-dose combination therapy leverages the complementary mechanisms of an angiotensin II receptor blocker (ARB) and a thiazide diuretic to provide synergistic effects on vascular tone and fluid balance. Clinically validated for efficacy and safety, it simplifies treatment regimens while supporting adherence in long-term hypertension management. Its dual-action formulation addresses both renin-angiotensin system inhibition and sodium excretion, making it a rational choice for patients inadequately controlled on monotherapy.
Features
- Contains irbesartan (ARB) and hydrochlorothiazide (thiazide diuretic) in fixed-dose combinations
- Available in strengths: 150 mg/12.5 mg, 300 mg/12.5 mg, and 300 mg/25 mg
- Once-daily dosing regimen
- Film-coated tablets for ease of swallowing
- Manufactured under strict pharmaceutical quality standards
- Prescription-only medication
Benefits
- Provides dual-mechanism blood pressure reduction through vasodilation and diuresis
- Improves medication adherence by consolidating two agents into one tablet
- Demonstrates proven efficacy in clinical trials for systolic and diastolic pressure reduction
- May reduce the risk of cardiovascular events associated with uncontrolled hypertension
- Offers flexible dosing options to accommodate individual patient needs and response
- Minimizes pill burden for patients on complex antihypertensive regimens
Common use
Avalide is indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents, in patients whose blood pressure is not adequately controlled on monotherapy. It is particularly suitable for patients who require additional blood pressure reduction beyond what irbesartan or hydrochlorothiazide alone can provide. The medication may be used as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. Clinical judgment should determine whether the fixed combination represents appropriate therapy based on individual patient characteristics and treatment goals.
Dosage and direction
The recommended starting dose is one Avalide 150 mg/12.5 mg tablet once daily. dosage may be titrated up to Avalide 300 mg/12.5 mg or 300 mg/25 mg after 2-4 weeks based on blood pressure response. The maximum recommended daily dose is irbesartan 300 mg/hydrochlorothiazide 25 mg. Administration should occur at approximately the same time each day, with or without food. Tablets should be swallowed whole with a glass of water; they should not be split, crushed, or chewed. dosage adjustment may be necessary for elderly patients or those with renal impairment.
Precautions
Periodic assessment of renal function is recommended, particularly in patients with pre-existing renal impairment. Serum electrolyte levels (especially potassium, sodium, and magnesium) should be monitored regularly, especially during initiation and after dosage adjustments. Use with caution in patients with impaired hepatic function or history of hepatic disease. May cause hypersensitivity reactions in patients with history of asthma or allergy. Caution should be exercised when administering to patients with systemic lupus erythematosus. Photosensitivity reactions may occur; patients should be advised to use sun protection. Orthostatic hypotension may occur, particularly in volume-depleted patients.
Contraindications
Hypersensitivity to irbesartan, hydrochlorothiazide, other sulfonamide-derived drugs, or any component of the formulation. Anuria. Concomitant use with aliskiren in patients with diabetes. Severe hepatic impairment. Pregnancy (second and third trimesters). Breastfeeding. Co-administration with lithium requires careful consideration and monitoring.
Possible side effects
Common adverse reactions (≥2%) include dizziness, fatigue, musculoskeletal pain, nausea/vomiting, and hyperkalemia. Less frequent side effects may include orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), increased serum creatinine, headache, diarrhea, and upper respiratory infection. Rare but serious adverse effects include angioedema, acute renal failure, pancreatitis, hepatic impairment, and severe skin reactions. Thiazide component may increase cholesterol and triglyceride levels. Some patients may experience photosensitivity reactions or gout attacks.
Drug interaction
May potentiate effects of other antihypertensive agents. NSAIDs may reduce antihypertensive effect and increase risk of renal impairment. Concomitant use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to hyperkalemia. May increase lithium levels and toxicity. Thiazides may enhance the effects of skeletal muscle relaxants and nondepolarizing neuromuscular blocking agents. Corticosteroids and ACTH may enhance electrolyte depletion. May alter the response to insulin and oral hypoglycemic agents. Cholestyramine and colestipol may reduce absorption of hydrochlorothiazide.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining blood pressure control. Patients should be advised to establish a routine for medication administration to minimize missed doses.
Overdose
Symptoms may include hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, electrolyte disturbances, and renal impairment. Management should include supportive measures with correction of dehydration and electrolyte imbalances. Gastric lavage may be considered if ingestion was recent. Hemodialysis is not effective for irbesartan removal but may help correct fluid and electrolyte imbalances associated with hydrochlorothiazide. Blood pressure support with intravenous fluids and vasopressors may be necessary. Close monitoring of vital signs, urine output, and electrolyte status is essential.
Storage
Store at room temperature (20-25°C or 68-77°F) in the original container. Protect from light and moisture. Keep tightly closed when not in use. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations or through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses to medication may vary. Healthcare professionals should exercise clinical judgment when prescribing Avalide, considering individual patient characteristics, contraindications, and potential drug interactions. Patients should be fully informed about the benefits and risks of therapy and monitored appropriately during treatment. Full prescribing information should be consulted before initiation of therapy.
Reviews
Clinical studies demonstrate that Avalide provides significant blood pressure reduction compared to component monotherapies. In randomized controlled trials, the combination therapy showed superior efficacy with approximately 70% of patients achieving target blood pressure goals. The combination was generally well-tolerated with a safety profile consistent with the individual components. Long-term extension studies support maintained efficacy and safety over 12 months of treatment. Real-world evidence suggests improved adherence rates compared to free combinations of the individual components.